This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information, and/or meta data obtained from platforms to improve current approaches for the early detection of organ confined premetastatic aggressive cancer and identifying precancerous lesions associated with a subsequent lethal phenotype. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to improve diagnostic performance, minimize/better manage overdiagnosis, and reduce false positives and false negatives. • The FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. • The projects will use various techniques, including artificial intelligence or virtual reality visualization techniques, to analyze data. • The FOA is open to various types of applicants, including nonprofits, for-profit organizations, and institutions of higher education. • The award ceiling and floor are not specified, and cost sharing is not required.